CONNECT WITH US
Web3 & Blockchain

Web3 & Blockchain

Eli Lilly (LLY) Stock Price Prediction: Lilly pulls back toward support as analysts stay constructive

Blockchain.News logo

Published on

Add as a preferred source on Google
Eli Lilly (LLY) Stock Price Prediction: Lilly pulls back toward support as analysts stay constructive

Eli Lilly (LLY) is trading at $1,369.97, below its short-term moving averages after a 2.52% 24-hour decline, but the broader structure still shows a constructive trend above the 50-day average. Fre...

Eli Lilly (LLY) is easing off recent highs rather than breaking down outright. The stock is at $1,369.97, down 2.52% over 24 hours, and it has slipped under the 7-day SMA of $1,414.69, the 20-day SMA of $1,407.70 and the 12-day EMA of $1,403.69. But it remains above the 50-day SMA of $1,303.14, which keeps the medium-term trend intact.

That matters because this looks more like a digestion phase than a trend failure. The volume backdrop supports that read: activity is running at 0.51x the 5-day average, which points to a low-volume pullback rather than an aggressive liquidation.

The company’s latest reported quarter was a clear step up. According to Eli Lilly’s October 29, 2026 release, third-quarter revenue rose 39% year over year to $24.4 billion, driven primarily by Mounjaro and Zepbound. Reported EPS increased 16% to $7.22, while non-GAAP EPS rose 7% to $7.48. Lilly also lifted the midpoint of its 2026 full-year revenue guidance by $5.5 billion to a range of $91.0 billion to $92.0 billion, which gives investors a stronger operating base to lean on.

That backdrop is why the street remains constructive despite the share-price strength already on the chart. RBC Capital reiterated an Outperform rating and a $1,600 price target on November 17, saying the December 7 Innovation Day is strategically important for highlighting growth beyond obesity.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.